Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells

Molecular Cancer Research

Volumn 10, Issue 12, 2012, Pages 1597-1606

  Wu, Yanyuan ^a,c,d   Ginther, Charles ^b,d   Kim, Juri ^a,c   Mosher, Nicole ^a,c   Chung, Seyung ^a,c   Slamon, Dennis ^b,d   Vadgama, Jaydutt V ^a,c,d  

^a Division of Cancer Research and Training   (United States)

^b Division of Hematology Oncology   (United States)

^c CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NERVE CELL ADHESION MOLECULE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR TWIST; TRASTUZUMAB; UVOMORULIN; WNT3 PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL INVASION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; BETA CATENIN; BREAST NEOPLASMS; CADHERINS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NUCLEAR PROTEINS; ORGANIC CATION TRANSPORT PROTEINS; PHENOTYPE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TWIST TRANSCRIPTION FACTOR; WNT SIGNALING PATHWAY; WNT3 PROTEIN;

EID: 84871392766     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0155-T     Document Type: Article

References (31)

1. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-60. (Pubitemid 36227628)
2. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64:2343-6. (Pubitemid 38523885)
3. Chan CT, Metz MZ, Kane SE. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoi-nositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res Treat 2005;91:187-201. (Pubitemid 40684931)
4. Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on 3D microenvironment. Breast Cancer Res Treat 2010;122:35-43.
5. Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV. FOXO1 is a target for HER2-overexpressing breast tumors. Cancer Res 2010;70:5475-85.
6. Wu Y, Mohamed H, Chillar R, Clayton S, Slamon D, Vadgama JV. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res 2008;10:R3
7. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoël MJ, Bertrand F, Cherqui G, Perret C, et al. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 2001;20:252-9. (Pubitemid 32150270)
8. Petrocelli T, Slingerland JM. PTEN deficiency: a role in mammary carcinogenesis. Breast Cancer Res 2001;3:356-60. (Pubitemid 34196360)
9. Persad S, Troussard AA, McPhee TR, Mulholland DJ, Dedhar S. Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol 2001;153:1161-74.
10. Hashimoto M, Sagara Y, Langford D, Everall IP, Mallory M, Everson A, et al. Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway. Implications for neuroprotection. J Biol Chem 2002;277:32985-91. (Pubitemid 34984813)
11. Howe LR, Brown AMC. Wnt signaling and breast cancer (Review). Cancer Biol Ther 2004;3:36-41.
12. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Ef ficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-over-expressing metastatic breast cancer. J Clin Oncol 2002;2:719-26. (Pubitemid 34111379)
13. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005;65:11118-28. (Pubitemid 41713383)
14. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelmen JA, et al.Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007;13:4909-19. (Pubitemid 47294799)
15. Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllo{combining double acute accent}si J, Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 2005;304:604-19. (Pubitemid 40321136)
16. Schlange T, Matsuda Y, Lienhard S, Huber A, Hynes NE. Autocrine Wnt signaling contributes to breast cancer cell proliferation via the canonical Wnt pathway and EGFR transactivation. Breast Cancer Res 2007;9:R63.
17. Kurayoshi M, Oue N,Yamamoto H, Kishida M, Inoue A, Asahara T, et al. Expression of Wnt-5 is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res 2006;66:10439-48. (Pubitemid 44799765)
18. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, et al. FZD4 as a mediator of ERG oncogene-induced Wnt signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2010;70:6735-45.
19. Kobune M, Chiba H, Kato J, Kato K, Nakamura K, Kawano Y, et al. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism. Mol Cancer Ther 2007;6:1774-84. (Pubitemid 46954054)
20. Lalli E, Wakil AE. The Wnt/beta-catenin pathway in adrenocortical development and cancer. Mol Cell Endocrinol 2010;332:32-7.
21. Kuorelahti A, Rulli S, Huhtaniemi I, Poutanen M. Human chorionic gonadotropin (hCG) up-regulates Wnt5 and Wnt7b in the mammary gland, and hCGβ transgenic female mice present with mammary gland tumors exhibiting characteristics of the Wnt/β-catenin pathway activation. Endocrinology 2007;148:3694-3703. (Pubitemid 47105831)
22. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010;16:3153-62.
23. Ayyanan A, Civenni G, Ciarloni L, Morel C, Mueller N, Lefort K, et al. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc Natl Acad Sci U S A 2006;103:3799-804. (Pubitemid 43376635)
24. Givenni G, Holbro T, Hynes NE. Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. EMBO 2003;4:166-71. (Pubitemid 36322158)
25. Yan L, Coletta LD, Powell LK, Shen J, Thames H, Aldaz MC, et al. Activation of the canonical Wnt/β-catenin pathway in ATF3-induced mammary tumors. PLoS One 2011;6:e16515.
26. Benhaj K, Akcali KC, Ozturk M. Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncol Rep 2006;15:701-7.
27. Yook JI, Li XY, Ota I, Hu C, Kim HS, Kim NH, et al. A Wnt-Axin2- GSK3β cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol 2006;8:1398- 406.
28. Yee DS, Tang Y, Li X, Liu Z, Guo Y, Ghaffar S, et al. The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol Cancer 2010;9:162.
29. Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL. TGFβ/TNFα-mediated epithelial-mesenchymal transition generates breast cancer stem cells with claudin-low phenotype. Cancer Res 2011, 71:4707-19.
30. Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgen L, Burmi R, et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behavior and involves modulation of β-catenin phosphorylation. Int J Cancer 2006;118:290-301. (Pubitemid 41779067)
31. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006;5:997-1014. (Pubitemid 44835127)